Our top pick for
ImmunoGen, Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 75 staff and has a trailing 12-month revenue of around USD$86.5 million.
Since the stock market crash in March caused by coronavirus, ImmunoGen's share price has had significant positive movement.
Its last market close was USD$5.75, which is 5.91% up on its pre-crash value of USD$5.41 and 194.87% up on the lowest point reached during the March crash when the shares fell as low as USD$1.95.
If you had bought USD$1,000 worth of ImmunoGen shares at the start of February 2020, those shares would have been worth USD$542.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,228.66.
|Latest market close||USD$5.75|
|52-week range||USD$1.95 - USD$6.79|
|50-day moving average||USD$4.126|
|200-day moving average||USD$4.2112|
|Wall St. target price||USD$8.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.19|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||7.68%|
|1 month (2020-10-30)||1.95%|
|3 months (2020-09-01)||53.74%|
|6 months (2020-06-01)||16.87%|
|1 year (2019-11-29)||59.28%|
|2 years (2018-11-30)||4.36%|
|3 years (2017-12-01)||-5.58%|
|5 years (2015-12-01)||-56.70%|
|Revenue TTM||USD$86.5 million|
|Gross profit TTM||USD$-32,251,000|
|Return on assets TTM||-10.9%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 17.3 million ImmunoGen shares held short by investors – that's known as ImmunoGen's "short interest". This figure is 10.4% up from 15.7 million last month.
There are a few different ways that this level of interest in shorting ImmunoGen shares can be evaluated.
ImmunoGen's "short interest ratio" (SIR) is the quantity of ImmunoGen shares currently shorted divided by the average quantity of ImmunoGen shares traded daily (recently around 2.3 million). ImmunoGen's SIR currently stands at 7.54. In other words for every 100,000 ImmunoGen shares traded daily on the market, roughly 7540 shares are currently held short.
However ImmunoGen's short interest can also be evaluated against the total number of ImmunoGen shares, or, against the total number of tradable ImmunoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoGen's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 ImmunoGen shares in existence, roughly 100 shares are currently held short) or 0.1114% of the tradable shares (for every 100,000 tradable ImmunoGen shares, roughly 111 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoGen.
Find out more about how you can short ImmunoGen stock.
We're not expecting ImmunoGen to pay a dividend over the next 12 months.
Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $1.95 up to $6.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 2.0419. This would suggest that ImmunoGen's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.